Question · asked by 1 review
Tocilizumab weekly vs placebo + 52‐week taper: Proportion of all‐cause mortality at ≥ 12 months
- Population
- adults aged over 50 years with giant cell arteritis
- Intervention
- Tocilizumab weekly
- Comparison
- placebo + 52‐week taper
- Outcome
- Proportion of all‐cause mortality at ≥ 12 months
The review found no eligible studies for this question.
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Tocilizumab weekly vs placebo + 52‐week taper Proportion of all‐cause mortality at ≥ 12 months · adults aged over 50 years with giant cell arteritis The review found no eligible studies for this question. Tocilizumab for giant cell arteritis (2022) · Cochrane Headline outcomes only | no estimate extracted | Not reported | No studies found |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Tocilizumab for giant cell arteritis 2022 · Cochrane Headline outcomes only | Not reported | Not extracted | Not assessed |
Related questions
The same intervention and outcome, asked in another population or against another comparator.
- Tocilizumab weekly vs placebo + 26‐week taper · adults aged over 50 years with giant cell arteritis · 1 review
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.